Human Immunodeficiency Virus Clinical Trials

22 recruiting

Frequently Asked Questions

Common questions about Human Immunodeficiency Virus clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 47 trials

Recruiting
Phase 3

A Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010)

Human Immunodeficiency Virus (HIV)HIV Pre-Exposure Prophylaxis
Merck Sharp & Dohme LLC4,580 enrolled27 locationsNCT07071623
Recruiting
Not Applicable

Guaranteed Income to Boost HIV Care Continuity and Suppression Post-Jail Release

HIV (Human Immunodeficiency Virus)
University of California, San Francisco33 enrolled1 locationNCT07115901
Recruiting
Not Applicable

Improving Access to HIV Testing for Children in Uganda

HIV (Human Immunodeficiency Virus)
University of California, San Francisco400 enrolled1 locationNCT07236905
Recruiting
Phase 3

A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)

Human Immunodeficiency Virus (HIV)HIV Pre-Exposure Prophylaxis
Merck Sharp & Dohme LLC4,390 enrolled70 locationsNCT07044297
Recruiting
Phase 1

Lenacapavir Intensification to Disrupt HIV Reservoirs in Virologically Suppressed People With HIV Receiving Antiretroviral Therapy

Human Immunodeficiency Virus
National Institute of Allergy and Infectious Diseases (NIAID)50 enrolled1 locationNCT06819176
Recruiting
Phase 2Phase 3

A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)

Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Merck Sharp & Dohme LLC570 enrolled24 locationsNCT07266831
Recruiting
Phase 2

Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Aged 4 Weeks to <12 Years and <45 kg (MK-1439-066)

Human Immunodeficiency Virus (HIV) Infection
Merck Sharp & Dohme LLC84 enrolled24 locationsNCT04375800
Recruiting
Not Applicable

Secondary Cervical Cancer Prevention of Vulnerable Women With HPV and HIV Co-infection in India

Cervical CancerHuman Papillomavirus (HPV) InfectionHuman Immunodeficiency Virus (HIV) Infection
University of California, Irvine420 enrolled1 locationNCT07209917
Recruiting

Voluntary HIV Screening in the General Population in France

Human Immunodeficiency Virus (HIV)
Université de Reims Champagne-Ardenne1,000 enrolled1 locationNCT07418385
Recruiting

Molecular Characterization of Viral-associated Tumors, Tumors Occurring in the Setting of HIV or Other Immune Disorders and Castleman Disease

Castleman's DiseaseKaposi's SarcomaHuman Immunodeficiency Virus+1 more
National Cancer Institute (NCI)280 enrolled1 locationNCT03300830
Recruiting
Phase 4

A Study of Reduced Dosing of the Nonavalent HPV Vaccine in Women Living With HIV

Human Papilloma VirusHPVHuman Immunodeficiency Virus
University of British Columbia275 enrolled10 locationsNCT05495906
Recruiting
Not Applicable

Strategies to AchieVe Viral Suppression for Youth With HIV

Human Immunodeficiency Virus (HIV) Infection
Johns Hopkins University288 enrolled1 locationNCT06886971
Recruiting

Universal Test and Connect for HIV Service Delivery in South Africa

Human Immunodeficiency VirusPre-exposure ProphylaxisEmergency Department+1 more
Johns Hopkins University2,000 enrolled1 locationNCT06408142
Recruiting
Phase 2

Effect of Empagliflozin on Metabolic Outcomes in Adults Living With HIV Receiving Dolutegravir-Based Therapy

Metabolic SyndromeObesity, OverweightHIV (Human Immunodeficiency Virus)
Abdelrahman Mahmoud66 enrolled1 locationNCT07336797
Recruiting

Questioning the Epidemiology of Asymptomatic TB

TuberculosisHIV (Human Immunodeficiency Virus)HIV+1 more
Barcelona Institute for Global Health6,770 enrolled1 locationNCT07312266
Recruiting
Not Applicable

Quitting Matters Human Immunodeficiency Virus Hybrid Trial

Smoking CessationCancer PreventionHuman Immunodeficiency Virus (HIV)+4 more
Wake Forest University Health Sciences314 enrolled1 locationNCT06883097
Recruiting
Phase 1

The DART DELIVER-02 Study

HIV (Human Immunodeficiency Virus)
University of North Carolina, Chapel Hill24 enrolled3 locationsNCT07217379
Recruiting
Not Applicable

The Eswatini PRISM Study on Adolescents Living With HIV

Psychological StressHuman Immunodeficiency Virus
Eswatini Nazarene Health Institutions140 enrolled1 locationNCT07101458
Recruiting
Not Applicable

Integrating Project YES! With WHO-Endorsed Mental Health Approaches Among Youth Living With HIV

AnxietyHIV (Human Immunodeficiency Virus)Mental Health+2 more
Johns Hopkins Bloomberg School of Public Health400 enrolled1 locationNCT07221201
Recruiting
Not Applicable

The SUSTAIN 2 Study - SUStained HIV Treatment for Adherence After Interruption in Care

Human Immunodeficiency Virus
Brigham and Women's Hospital310 enrolled1 locationNCT06554223